News

Distinguishing between primary and secondary cold agglutinin disease (CAD), as well as understanding if cancer is the underlying cause of secondary CAD, is critical to ensure patients get the right treatment, according to a recent review study. Primary CAD — sometimes known simply as CAD — is not…

Decisions about cold agglutinin disease (CAD) treatment need to be made on a case-by-case basis, considering each patient’s specific situation, a pair of scientists in Italy argued in a review study. The scientists reviewed available and up-and coming treatment options for CAD, giving advice for how best to employ…

Obinutuzumab, a B cell-depleting medication approved for certain blood cancers, was effective for controlling primary cold agglutinin disease (CAD) in a woman in China, according to a case study. The treatment “shows a promising role in CAD which might [warrant] further investigation,” researchers wrote in the case study, “…

Enjaymo (sutimlimab), the only approved treatment for cold agglutinin disease (CAD), needs to be about 80% cheaper or be used for a maximum limit of 1.5 years to meet conventional thresholds for cost-effectiveness in the U.S. That’s according to a cost-effectiveness analysis that was based on data from…

A step-by-step process is needed to accurately diagnose cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia (AIHA), according to a report. This process involves the detection of blood cell destruction, establishing whether this is due to an immune attack, and finally zeroing in on the specific…

Vermont Governor Phil Scott has signed into law a bill that improves access to the right medication at the right time by requiring both private and public health insurers to make timely exceptions to their step therapy policies. Misuse of step therapy protocols, which require patients to “fail first” on…

A third of adults with severe autoimmune hemolytic anemia (AIHA) — a group of rare conditions that includes cold agglutinin disease (CAD) — responded to intravenous immunoglobulins (IVIG), when used as an add-on therapy, after seven days, according to a retrospective study from France. The study also detailed a…

Maintaining a high temperature with the equipment used for plasmapheresis therapy in people with cold agglutinin disease (CAD), along with the environment and patients, may help prevent the risk of red blood cell clumping and destruction during the procedure, a new case report suggests. “Although our approach still…

A woman with both cold agglutinin disease (CAD) and myelodysplastic syndrome, a rare blood cancer, responded well to treatment with a moderate dose of the corticosteroid prednisolone followed by cyclosporine, an immunosuppressant, a case study reports. While corticosteroids usually fail to treat CAD, they were used in this case…

Daratumumab, given on its own, could be a treatment for adults with hard to treat cold agglutinin disease (CAD), with more than half of the patients in a small study in Europe responding well to the therapy. The findings add to previous reports about the successful use of…